<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424554</url>
  </required_header>
  <id_info>
    <org_study_id>P04602</org_study_id>
    <nct_id>NCT00424554</nct_id>
  </id_info>
  <brief_title>Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)</brief_title>
  <official_title>A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the effect of a two-week pre-surgery treatment
      with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid)
      methyltransferase (MGMT) activity in patients with gliomas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2006</start_date>
  <completion_date type="Actual">February 16, 2011</completion_date>
  <primary_completion_date type="Actual">January 11, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery</measure>
    <time_frame>14 days</time_frame>
    <description>An experimental assay was developed to measure MGMT levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants Who Experienced Grade 3 or 4 Toxicities</measure>
    <time_frame>12 months</time_frame>
    <description>Grade 3 was defined as severe per Common Terminology Criteria for Adverse Events (CTCAE).
Grade 4 was defined as life-threatening per CTCAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)</measure>
    <time_frame>12 months</time_frame>
    <description>An AE was defined as any event which was adverse, including what were commonly described as adverse or undesirable experiences, adverse events, adverse reactions, side effects, or death due to any cause associated with, or observed in conjunction with the use of a drug, biological product, or device in humans, whether or not considered related to the use of that product. Additionally, any event which was associated with, or observed in conjunction with product overdose whether accidental or intentional, or product abuse and/or withdrawal was also considered an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Temozolomide in the Serum, Cerebrospinal Fluid, and Brain Tumor</measure>
    <time_frame>14 days</time_frame>
    <description>No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGMT Activity in the Brain Tumor Tissues by Temozolomide Levels</measure>
    <time_frame>14 days</time_frame>
    <description>No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Temozolomide treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
    <arm_group_label>Temozolomide treatment</arm_group_label>
    <other_name>SCH 052365</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a brain tumor with high probability of being a glioma as detected by
             Magnetic Resonance Imaging (MRI). These would include newly diagnosed tumors or
             potentially recurrent gliomas.

          -  No prior treatment for the tumor including chemotherapy or radiotherapy.

          -  Amenable to surgery for biopsy or resection of the brain tumor. Surgically confirmed
             diagnosis of glioma (glioblastoma multiforme [GBM], anaplastic astrocytoma [AA],
             anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA], astrocytoma [A]
             or oligodendroglioma [O]) will be

        required for patients to be maintained in the study. Those not fulfilling this requirement
        will be discontinued and will be replaced.

          -  Use of medically approved contraception in fertile males and females.

          -  Women with childbearing potential must have a negative urine or serum

        pregnancy test (urinary excretion or serum level of beta-Human Chorionic

        Gonadotropin [bHCG]) within 72 hours of randomization.

          -  Karnofsky Performance Status score &gt;= 70%.

          -  Signed informed consent form

        Exclusion Criteria:

          -  Prior chemotherapy.

          -  Prior radiotherapy at the tumor site.

          -  History of non-compliance to other therapies.

          -  Inadequate haematological, renal and hepatic function according to all of the
             following laboratory values (to be performed within 14 days, inclusive, prior to study
             inclusion):

               -  Absolute neutrophil count ≤1.5 x 10^9/L;

               -  Platelets ≤100 x 10^9/L;

               -  Haemoglobin &lt;90 g/L;

               -  Serum creatinine ≥1.5 times upper limit of laboratory normal;

               -  Total serum bilirubin ≥1.5 times upper limit of laboratory normal (ULN);

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.0 ULN;

               -  Alkaline phosphatase of &gt; 2.5 ULN.

          -  Known Human Immunodeficiency Virus [HIV] infection.

          -  Known chronic hepatitis B or hepatitis C infection.

          -  Any other serious medical condition according to the medical judgment of the physician
             prior to inclusion in the study.

          -  Any medical condition, which could interfere with oral medication intake (e.g.,
             frequent vomiting, partial bowel obstruction).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2007</study_first_posted>
  <results_first_submitted>June 3, 2011</results_first_submitted>
  <results_first_submitted_qc>June 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2011</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide (TMZ)</title>
          <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
        </group>
        <group group_id="P2">
          <title>No Intervention</title>
          <description>No pre-surgery treatment with temozolomide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide (TMZ)</title>
          <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
        </group>
        <group group_id="B2">
          <title>No Intervention</title>
          <description>No pre-surgery treatment with temozolomide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age range: 18-75 years</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery</title>
        <description>An experimental assay was developed to measure MGMT levels.</description>
        <time_frame>14 days</time_frame>
        <population>All participants for which a MGMT activity assay could be
performed</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide (TMZ)</title>
            <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>No pre-surgery treatment with temozolomide</description>
          </group>
        </group_list>
        <measure>
          <title>MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery</title>
          <description>An experimental assay was developed to measure MGMT levels.</description>
          <population>All participants for which a MGMT activity assay could be
performed</population>
          <units>fmol/mg of proteins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.7" spread="288.5"/>
                    <measurement group_id="O2" value="105.1" spread="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants Who Experienced Grade 3 or 4 Toxicities</title>
        <description>Grade 3 was defined as severe per Common Terminology Criteria for Adverse Events (CTCAE).
Grade 4 was defined as life-threatening per CTCAE.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide (TMZ)</title>
            <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>No pre-surgery treatment with temozolomide</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants Who Experienced Grade 3 or 4 Toxicities</title>
          <description>Grade 3 was defined as severe per Common Terminology Criteria for Adverse Events (CTCAE).
Grade 4 was defined as life-threatening per CTCAE.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)</title>
        <description>An AE was defined as any event which was adverse, including what were commonly described as adverse or undesirable experiences, adverse events, adverse reactions, side effects, or death due to any cause associated with, or observed in conjunction with the use of a drug, biological product, or device in humans, whether or not considered related to the use of that product. Additionally, any event which was associated with, or observed in conjunction with product overdose whether accidental or intentional, or product abuse and/or withdrawal was also considered an AE.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide (TMZ)</title>
            <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>No pre-surgery treatment with temozolomide</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)</title>
          <description>An AE was defined as any event which was adverse, including what were commonly described as adverse or undesirable experiences, adverse events, adverse reactions, side effects, or death due to any cause associated with, or observed in conjunction with the use of a drug, biological product, or device in humans, whether or not considered related to the use of that product. Additionally, any event which was associated with, or observed in conjunction with product overdose whether accidental or intentional, or product abuse and/or withdrawal was also considered an AE.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Temozolomide in the Serum, Cerebrospinal Fluid, and Brain Tumor</title>
        <description>No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide (TMZ)</title>
            <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>No pre-surgery treatment with temozolomide</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Temozolomide in the Serum, Cerebrospinal Fluid, and Brain Tumor</title>
          <description>No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MGMT Activity in the Brain Tumor Tissues by Temozolomide Levels</title>
        <description>No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide (TMZ)</title>
            <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>No pre-surgery treatment with temozolomide</description>
          </group>
        </group_list>
        <measure>
          <title>MGMT Activity in the Brain Tumor Tissues by Temozolomide Levels</title>
          <description>No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide</title>
          <description>Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also have been given at the same dose for up to 28 days after surgery, per investigator discretion.</description>
        </group>
        <group group_id="E2">
          <title>No Intervention</title>
          <description>No pre-surgery treatment with temozolomide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COMPLEX PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VISUAL FIELD DEFECT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SKIN IRRITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator (PI) agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review, without limitation, including editorial rights. If the parties disagree, the PI agrees to meet with the sponsor to discuss and resolve any such issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The assay developed to measure MGMT activity had high variability.
The TMZ assay was unable to detect the low levels of the drug due to the relatively low dose and short half life of TMZ.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

